Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective
Authors:
- 25 April 2022
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 37 (5) , 905-916
Abstract
Purpose To assess the cost-effectiveness of evolocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, compared with ezetimibe, both added to background statin therapy in patients with recent acute coronary syndrome (ACS) events (in the past 12 months) and low-density lipoprotein cholesterol (LDL-C) levels ≥ 100 mg/dL in China. Methods A health economic evaluation was performed from a Chinese healthcare perspective, using a Markov model over a lifetime horizon based on a baseline cardiovascular (CV) event rate from claims database data and efficacy from the FOURIER trial. The health benefit was reflected in the decrease of LDL-C level, which led to a decrease of cardiovascular events. The costs of cardiovascular events and the utility value of each health state were derived from the published literature. Sensitivity analyses were conducted to evaluate the effects of uncertainty in parameters and the robustness of the model. The cost-effectiveness of evolocumab was also explored in patients with recent myocardial infarction (MI), at very high risk (VHR) of atherosclerotic cardiovascular disease (ASCVD), and homozygous familiar hypercholesterolemia (HoFH). Results In patients with recent ACS, evolocumab was associated with incremental quality-adjusted life-years (QALYs) of 1.33 and incremental costs of 115,782 yuan versus ezetimibe, both with background statin therapy, resulting in an incremental cost-effectiveness ratio (ICER) of 87,050 yuan per QALY gained. The probability of evolocumab + statins being cost-effective at a threshold of 217,341 yuan (three times per capita GDP, 2020), compared with ezetimibe + statins, was 100% in patients with recent ACS, recent MI, VHR ASCVD, and HoFH. Conclusion Compared with ezetimibe + statins, the combination of evolocumab + statins was found to be cost-effective at a threshold of 217,341 yuan (three times per capita GDP, 2020) in patients with recent ACS events in China.Keywords
This publication has 27 references indexed in Scilit:
- A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering TherapiesPharmacoEconomics, 2016
- Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment centerLipids in Health and Disease, 2016
- Cost‐Effectiveness ofLDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United StatesClinical Cardiology, 2016
- TWO-YEAR OUTCOMES POST DISCHARGE IN CHINESE PATIENTS WITH ACUTE CORONARY SYNDROME: FINDINGS FROM THE EPICOR ASIA STUDYJACC, 2016
- The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin TherapyJournal of Pharmacy & Pharmaceutical Sciences, 2016
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine, 2015
- An International Model to Predict Recurrent Cardiovascular DiseaseThe American Journal of Medicine, 2012
- Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statinsYearbook of Medicine, 2007
- Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine, 2005
- By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?BMJ, 1994